国际原子能机构支持成员国生产靶向α治疗放射性药物的活动。

IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals.

作者信息

Jalilian A R, Kleynhans J, Bouziotis P, Bruchertseifer F, Chakraborty S, De Blois E, Denecke M, Elboga U, Gizawy M, Horak C, Jang J, Korde A, Majkowska-Pilip A, Mdlophane A, Ocampo-Garcia B, Selivanova S V, Starovoitova V, Wojdowska W, Zeevaart J R, Radchenko V

机构信息

Radiochemistry and Radiation Technology Section, Division of Physical and Chemical Sciences, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Austria.

Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and pharmacological sciences, Katholieke Universiteit Leuven, Belgium.

出版信息

Nucl Med Biol. 2025 May-Jun;144-145:109008. doi: 10.1016/j.nucmedbio.2025.109008. Epub 2025 Mar 3.

DOI:10.1016/j.nucmedbio.2025.109008

PMID:40073757

Abstract

Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on Ac-radiopharmaceuticals.

摘要

由于国际原子能机构（IAEA）成员国对普遍实施靶向放射性核素治疗（TRT）的兴趣日益浓厚，对发射α粒子的放射性核素和放射性药物的需求巨大。作为放射性核素和平应用的国际平台，IAEA通过技术会议、研讨会、出版物和会议支持、IAEA协调研究项目（CRP）和技术合作计划（TC），开展了多项活动，重点关注发射α粒子的放射性核素和放射性药物的生产及质量控制，以及该领域的能力建设。本文综述了IAEA在用于靶向α治疗（TAT）的发射α粒子的放射性药物的生产和质量控制方面的活动，以及未来步骤的路线图，包括但不限于正在进行的关于锕系放射性药物的CRP。